Combination treatment for double or triple hit lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs for a type of lymphoma that is harder to treat. The goal is to improve outcomes for patients aged 65 and older who have this specific genetic feature.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of diffuse large B-cell lymphoma that is CD20 positive.
- Your lymphoma has a double or triple hit genetic change.
- You are at least 65 years old.
- You are generally able to take care of yourself (ECOG score 0, 1, or 2).
- You have never had another cancer, except for certain non-melanoma skin cancers or cervical cancer in situ.
- Your doctor expects you to live at least 6 more months.
- Your heart and major organs are working well enough (no severe heart, kidney, liver, or blood problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
This trial tests a combination of medications for adults aged 60 and older with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This study tests a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) for older adults newly diagnosed with a certain type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this combination is safe and effective for people who may not be able to handle standard, more intense chemotherapy.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
Hear when a new DHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.